Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PREP | P48147 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272607 | 0.89 | PREP (0.37) | ALDH1A1KDM4ELMNAMAPTPOLB | |
| SCHEMBL2280035 | 0.77 | POLB (0.48) | ALDH1A1KDM4ELMNAMAPTPOLB | |
| SCHEMBL3444680 | 0.76 | ALDH1A1 (0.62) | ALDH1A1KDM4ELMNAMAPTPOLB | |
| SCHEMBL21820677 | 0.75 | SLC6A2 (0.51) | ALDH1A1KDM4ELMNAMAPTPOLB | |
| SCHEMBL17105779 | 0.74 | KMT2A (0.34) | KMT2ACA12CA1CA9 | |
| SCHEMBL2280037 | 0.74 | BCHE (0.34) | — | |
| SCHEMBL6763899 | 0.73 | PREP (0.53) | ALDH1A1KDM4EPREPCA12CA1 | |
| SCHEMBL8705852 | 0.73 | HRH3 (0.43) | PREPOPRM1CA12CA1CA9 | |
| SCHEMBL1019336 | 0.73 | ALDH1A1 (0.66) | ALDH1A1KDM4ELMNAMAPTPOLB | |
| SCHEMBL624690 | 0.72 | MEN1 (0.54) | ALDH1A1KDM4ELMNAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066329-B1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOBUTYLMETHYLAMINES | REVIVA PHARMACEUTICALS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-9302981-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20140194508-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8669285-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130231386-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8445714-B2 | Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8372883-B2 | Methods of using cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8338632-B2 | Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110263704-A1 | Methods of Using Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263888-A1 | Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263877-A1 | Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7989500-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| EP-2066329-A2 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | Reviva Pharmaceuticals, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080139663-A1 | Cycloalkylmethylamine analogs; use treating obesity or related co-morbid indications | REVIVA PHARMACEUTICALS, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008034142-A2 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263704-A1 | Methods of Using Cycloalkylmethylamines | AADAC, PNMT, INMT | ALDH1A1 828/4885KDM4E 728/4885LMNA 3042/4885 |
| US-20110263888-A1 | Cycloalkylmethylamines | AADAC, GPR119, INMT | ALDH1A1 794/4885KDM4E 648/4885LMNA 3131/4885 |
| US-20140194508-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | AADAC, INMT, AADAT | ALDH1A1 1066/4885KDM4E 556/4885LMNA 2928/4885 |
| US-20080139663-A1 | Cycloalkylmethylamine analogs; use treating obesity or related co-morbid indications | AADAC, GPR119, MC4R | ALDH1A1 737/4885KDM4E 787/4885LMNA 3837/4885 |
| US-20110263877-A1 | Cycloalkylmethylamines | AADAC, GPR119, INMT | ALDH1A1 794/4885KDM4E 648/4885LMNA 3131/4885 |
| US-20130231386-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | AADAC, INMT, AADAT | ALDH1A1 1066/4885KDM4E 556/4885LMNA 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.